Analysts now predict that the GLP-1 market could reach $71 billion by 2032, driven by increasing demand for these medications in the treatment of obesity, type 2 diabetes, and cardiovascular conditions
And, in fact, the study itself offers data to refute this conclusion: In all 49 cases studied, the "patient" funneled was a fictious patient seeking a drug with covert intent to measure the friction of access (to a drug they had no real-world medical necessity to receive)
Prior to sample loading the C18 disk was prepared by sequential treatment with methanol (20 L), acetonitrile/water/TFA (solvent B, 20 L, 80/20/0.1, v/v/v) and finally with solvent A (20 L)
Leukotriene B4 antagonism ameliorates experimental lymphedema
Pharmacy benefit managers, the drug middlemen that play a key role in the industry, reimburse pharmacies less than what they pay to acquire the drugs, Brunner said